We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other income stocks.
When it comes to income investing, dividend stocks are often the first choice for investors. These stocks offer regular payouts to shareholders, which are seen as a way to steadily increase income over time. This approach is backed by data. A report from Hartford Funds revealed that dividends have accounted for 39% of total returns on average since the 1940s. The report also highlighted that stocks with high dividend payouts have not only outperformed other dividend-paying stocks but have done so with lower volatility.
Income factor plays a crucial role in investing, as it can significantly boost overall returns, helping investors achieve the portfolio growth needed to meet their financial objectives. A study by Eagle Investment Management highlighted the income potential of dividend-paying stocks. The study compared the returns of a hypothetical $1,000,000 investment made on December 31, 2012, in the Dividend Aristocrats Index—composed of companies that have consistently raised their dividends for 25 years—with the broader market, assuming dividends were reinvested. According to the report, by 2022, the $1,000,000 investment in Dividend Aristocrats would have generated $93,212 in income, compared to just $55,726 from the market. This stark difference emphasized the greater income potential of dividend aristocrats over the broader market. Although this is a historical example, it underscores the importance of not only prioritizing dividends but also focusing on their growth to enhance a portfolio’s income stream over time.
Also read: 12 Best REIT Dividend Stocks To Buy for 2024
Dividend investing is not a quick path to success; it requires patience and a long-term approach. Over time, high-yielding dividend stocks tend to outperform those that don’t pay dividends. According to the French Data Library, while non-dividend-payers may lead the market in certain years, they generally fall short in the long run. Dividend-payers, especially those with higher yields, have consistently outperformed non-payers and even the broader market. The report, which examined returns from 1927 to 2023, found that non-dividend-payers delivered an annualized return of 8.7%, while high-yield stocks returned 10.9%. In comparison, the overall market returned 9.7% during the same period.
The report outlined several reasons why dividend-paying stocks tend to outperform others. According to the report, investing in dividend-payers helps filter out the most speculative stocks, as these companies are usually well-established and confident in their cash flow, allowing them to return cash to shareholders. Moreover, dividend-payers are more commonly found in the value segment of the market, and stocks with lower prices and expectations have historically performed well. Dividend payers often build a loyal shareholder base, as investors relying on income from their holdings are less likely to sell due to negative news. Lastly, committing to paying dividends fosters discipline within companies. Executives, tempted by the prospect of using excess cash for acquisitions or speculative projects, are instead compelled to act cautiously and prioritize maintaining dividend payouts. For this reason, investors tend to focus on companies with a proven history of strong dividend growth and high yields. In this article, we will further take a look at some of the best income stocks to buy according to analysts.
Our Methodology:
To compile this article, we screened for stocks known for their consistent dividend track records and sustained shareholder payouts over an extended period. This group reflects stability and long-term performance in dividend payouts. From this list, we further refined our selection criteria by identifying stocks with a projected upside potential of over 10% based on analyst price targets. The stocks are ranked according to their upside potential, as of December 13. We also considered hedge fund sentiment around each stock in Insider Monkey’s database, as of the third quarter of 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Upside Potential as of December 13: 32.12%
Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that manufactures and develops a wide range of medicines for serious ailments. In fiscal Q4 2024, the company reported $11.4 billion in revenue, marking a 20.5% increase from the same quarter last year. The company saw strong growth from Mounjaro and Zepbound, as well as a significant 17% rise in non-incretin revenue. This overall growth, driven by its oncology, immunology, and neuroscience portfolios, was compared to the results from Q3 2023.
Eli Lilly and Company (NYSE:LLY) received encouraging news for its weight loss programs, as President Joe Biden recently suggested expanding Medicare and Medicaid coverage to include these medications. If the proposal is approved, it could make these treatments accessible to millions more patients, potentially leading to a significant increase in sales. Although the proposal’s outcome is still uncertain, the market remains hopeful about the potential advantages for Eli Lilly. Due to these positive developments, the stock has surged by over 33.4% since the start of 2024.
Aristotle Atlantic Partners, LLC made the following comment about LLY in its Q3 2024 investor letter.
“Eli Lilly and Company (NYSE:LLY) is a leading pharmaceutical company that develops diabetes, oncology, immunology and neuroscience medicines. The company generates over half of its revenue in the U.S. from its leading drugs Trulicity, Verzenio and Taltz. The company operates in a single business segment: human pharmaceutical products.
Eli Lilly has a deep pipeline in treatment areas focused on metabolic disorders, oncology, immunology and central nervous system disorders. Currently, there are two phase-three assets: orforglipron, an oral GLP-1, and retatrutide, a triple incretin agonist, which could possibly expand upon the potential success of Mounjaro. We believe that Mounjaro has the potential to commercialize beyond Type 2 diabetes and obesity, potentially in the areas mentioned above of heart disease, sleep apnea, fatty liver disease and chronic kidney disease. We believe the premium valuation is supported by this outsized growth profile.”
On December 10, Eli Lilly and Company (NYSE:LLY) hiked its quarterly dividend by 15.4% to $1.50 per share. Through this increase, the company stretched its dividend growth streak to 11 years, earning it a reputation as one of the best dividend stocks. The stock offers a dividend yield of 0.76%, as of December 13.
The number of hedge funds tracked by Insider Monkey holding stakes in Eli Lilly and Company (NYSE:LLY) increased to 106 in Q3 2024, from 100 in the previous quarter. The total value of these holdings now exceeds $18.5 billion.
Overall LLY ranks 1st on our list of the best income stocks to buy according to analysts. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
